Ranbaxy to launch Rocaltrol(R) in US soon

Ranbaxy Pharmaceuticals Inc (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Ltd (RLL), announced an agreement with Validus Pharmaceuticals LLC (Validus) to market and distribute an authorised generic version of Rocaltrol(R) (calcitriol) in both softgel capsules and an oral liquid formulation.

Overall market sales for calcitriol softgel capsules and oral liquid were $70 million.

Rocaltrol(R) is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure not yet on dialysis, and in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis.

Rocaltrol(R) is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism.

“Ranbaxy was very pleased to be selected by Validus as their distribution partner for an authorised generic version of Rocaltrol(R). This product represents an excellent commercial opportunity for Ranbaxy which will increased our visibility and presence in the US healthcare system. We look forward to a long and prosperous partnership with Validus,” said Jim Mechan, vice president of sales and distribution of RPI.

Ranbaxy will launch the product immediately to all classes of trade in the US market, and expects to be the only generic company offering all forms and strengths of generic Rocaltrol(R).